Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients

Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multi-medical center in Kore...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-01, Vol.14 (2), p.385
Main Authors: Yim, Sun Young, Chun, Ho Soo, Lee, Jae Seung, Lim, Ji-Hwan, Kim, Tae Hyung, Kim, Beom Kyung, Kim, Seung Up, Park, Jun Yong, Ahn, Sang Hoon, Kim, Gyoung Min, Won, Jong Yun, Seo, Yeon Seok, Kim, Yun Hwan, Um, Soon Ho, Kim, Do Young
Format: Article
Language:English
Subjects:
Cancer therapies
Cirrhosis
Disease control
Hepatitis
Hepatocellular carcinoma
Liver cancer
Liver cirrhosis
Magnetic resonance imaging
Metastases
Mortality
Multivariate analysis
Patients
Portal vein
Radiation
Radiation therapy
Side effects
Survival
Thrombosis
Tumors
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multi-medical center in Korea. A total of 149 patients treated with TARE from 2008-2014 were recruited. The pre-treatment HCC stage was classified according to the BCLC stage, of which C and D were defined as advanced HCC. Advanced HCC stage and Child-Turcotte-Pugh (CTP) score A were identified in 62 (42%) and 134 (90%) patients, respectively. Portal vein thrombosis (PVT) was identified in 58 patients (38.9%). The median time to progression (TTP) was 14 months, and the median overall survival (OS) and progression-free survival (PFS) were 18.6 and 8.9 months, respectively. The overall tumor response was 47%, and the disease control rate was 78%. OS and PFS differed significantly according to the presence of liver cirrhosis, extrahepatic metastasis, tumor response and curative treatment after TARE (all, < 0.05). Multiple tumors and major PVT were other independent factors related to OS, while the des-gamma carboxy protein level predicted PFS (all, < 0.05). Tumor size was an independent predictor of tumor response. TTP, OS and PFS all differed among BCLC stages. The serious adverse effect after TARE was clinically not significant. Therefore, TARE is safe and effective in treating early to advanced HCCs.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14020385